tbuckley/cabot-search huggingface dataset:
FRI0213 Identification of Synovitis in Patients with Rheumatoid Arthritis in Clinical Remission during Therapy with Tocilizumab
Authors: E. Panasyuk, A. Smirnov, E. Fedorenko, T. Gavva, E. Gubar, E. Loginova, G. Lukina, E. Luchikhina, E. Tsvetkova, A. Avdeeva, E. Alexandrova, E. Nasonov
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The aim of therapy rheumatoid arthritis (RA) is the achievement of remission of the disease and slowing destruction of the joints. Tocilizumab (TCZ), anti-interleukin-6 receptor monoclonal antibody was used in treatment of active RA. TCZ has a rapid positive effect on the clinical manifestations and laboratory disoders, slowing destruction of joints in RA. <h3>Objectives</h3> To assess the effect of TCZ on synovitis on MRI of bilateral wrist and metacarpophalangeal joints in accordance with the OMERACT RA MRI scoring system (RAMRIS). <h3>Methods</h3> 43 adult patients with active RA were enrolled in the open label, phase IV trial to confirm the effectiveness and safety TCZ. Average age (median, interquartile range) 50,5 (43,0–55,0) years, duration of RA 56,5 (23,0–81,0) months, RF (+) 81%, ACCP (+) 77%. Patient had to be naive to biologics and have moderate to severe active RA (based on the 1987 ACR criteria). Patients remained on stable doses of disease-modifying antirheumatic drugs and received TCZ 8 mg/kg every 4 weeks for 24 weeks (total 6 infusions). Disease remission was assessed according to the criteria of EULAR and EULAR/ACR 2011. MRI performed at 0 and 24 weeks of observation. <h3>Results</h3> Before therapy indices DAS28 (6,4; 5,9–7,0), CDAI (41,5; 32,0–53,0) and SDAI (45,0; 36,2–57,0) corresponded to high activity of RA. The value of DAS28 to 24 weeks of treatment was 2,1; 1,3–2,8, p&lt;0.05. Indicators SDAI and CDAI up to 24th week match the low activity of RA (4,4; 2,0–8,8 and 3,6; 1,4–7,6, respectively). Remission was achieved by 24 weeks of treatment on indices: DAS28&lt;2.6 for 30 patients (71%), CDAI&lt;2.8 to 14 (33%), SDAI&lt;3.3 to 13 (31%) and according to the criteria of ACR/EULAR 2011 (Boolean) – 10 (24%). MRI of the bilateral wrist and metacarpophalangeal joints was performed for patients who achieved remission according to the DAS28 criteria (n=27) and Boolean (n=10). Synovitis was detected in 81.5% and 80%, osteitis in 11.1% and 10% of patients, respectively. <h3>Conclusions</h3> Despite the pronounced clinical effect of TCZ in patients with RA and remission according to the criteria of DAS28 and ACR/EULAR, synovitis was detected in most patients. MRI examination allows to observe the patients during the therapy to achieve complete remission of the disease. <h3>Disclosure of Interest</h3> None declared
FRI0480 Thiol/disulphide Homeostasis in Familial Mediterranean Fever: Table 1.
Authors: A. Doğru, A. Balkarlı, G.Y. Cetin, S. Neselioglu, O. Erel, M. Sahin, S.E. Tunc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Familial Mediterranean fever (FMF) is an autoinflammatory disease that include recurrent episodes of peritonitis, pleuritis, and arthritis, with accompanying fever. FMF is caused by mutations in MEFV and typically diagnosed during childhood. Thiol/disulphide homeostasis, marker of oxidative stress, is associated with an increased in inflammatory cytokines in many inflammatory diseases. <h3>Objectives</h3> We aimed to investigate the dynamic thiol/disulphide homeostasis in patients with FMF during attact free period. <h3>Methods</h3> Fifty five patients with FMF during attact free period, 55 patients with Ankylosing Spondylitis (AS) during inactive period and 55 age-and sex matched controls were included in the study. Native thiol, total thiol and disulphide levels were studied by the Erel and Neşelioğlu method. <h3>Results</h3> Total thiol and disulphide levels were significantly lower in FMF group compared to healthy controls. Native thiol levels were detected to be significantly increased in FMF groups compare to AS group. However, total thiol levels were similar in FMF and AS group. Ratios obtained using plasma native thiol, total thiol, and disulphide levels differed significantly between the FMF, AS and the control group. <h3>Conclusions</h3> Thiol levels, an important anti-oxidant, was found to be significantly lower. Subclinical inflamation may be continued in FMF patients during attact free period. Randomised controlled trials with large patient populations might help clarify this issue. <h3>Disclosure of Interest</h3> None declared
The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?
Authors: Roberto Latagliata, Marco Montanaro, Michele Cedrone, Nicoletta Villivà, Raffaele Porrini, Francesca Spirito, Angela Rago, Sabrina Leonetti Crescenzi, Antonio Spadea, Marianna De Muro, Ettore Cotroneo, Massimo Breccia, Erminia Baldacci, Cinzia De Gregoris, Barbara Anaclerico, Stefano Felici, Carla Ruscio, Jonny Di Giandomenico, Luca Franceschini, Gloria Pessina, Giuseppe Cimino, Enrico Montefusco, Agostino Tafuri, Giuseppe Avvisati, Ignazio Majolino, Maria Gabriella Mazzucconi, Giuliana Alimena, Alessandro Andriani
Journal: Blood (2012)
TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma
Authors: Owen A. O'Connor, Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, Suzanne Jones, John G Kuhn, Hari P. Miskin, Peter Sportelli, Swaroop Vakkalanka, Howard A. Burris
Journal: Blood (2015)
SURG-14LOW-GRADE GLIOMA WITH FOCI OF EARLY TRANSFORMATION BEHAVING IN AN INDOLENT FASHION FOLLOWING EXTENSIVE SURGICAL RESECTION
Authors: John Goodden, Yahia Al-Tamimi, Tufail Patankar, Jeremy MacMullen-Price, Daniel O'Hara, Carmel Loughrey, Aruna Chakrabarty, Paul Roberts, Hugues Duffau, Paul Chumas
Journal: Neuro-Oncology (2015)
The Microarray Signature of Rhesus Macaque CD34+CD123 (IL-3 Receptor)+ Hematopoietic Stem/Progenitor Cells Isolated Following Mobilization with Plerixafor Alone or in Combination with Granulocyte Colony-Stimulating Factor (G-CSF)
Authors: Robert E. Donahue, Ping Jin, Johanna I. Klinman, Aylin C. Bonifacino, Mark E. Metzger, David Stroncek
Journal: Blood (2011)
HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling
Authors: Roland Walter, Kuan-Ting Pan, Carmen Doebele, Federico Comoglio, Katarzyna Tomska, Hanibal Bohnenberger, Ryan M. Young, Laura Jacobs, Ulrich Keller, Halvard Bönig, Michael Engelke, Andreas Rosenwald, Henning Urlaub, Louis M. Staudt, Hubert Serve, Thorsten Zenz, Thomas Oellerich
Journal: Blood (2016)
Characteristics of the TCR Vbeta Repertoire and Identical Clonally Expanded T Cells in Chronic Myeloid Leukemia Patients in Advanced Phase with ABL Mutations
Authors: Ling Xu, Yuhong Lu, Jing Lai, Wei Yu, Zhenyi Jin, Yan Xu, Jie Chen, Xianfeng Zha, Shaohua Chen, Lijian Yang, Yangqiu Li
Journal: Blood (2015)
The Southern French Registry of Genetic Hemochromatosis, a Tool for Determination of Clinical Prevalence and Genotype Penetrance of the Disorder.
Authors: Patricia Aguilar-Martinez, Michael Bismuth, Francois Blanc, Pierre Blanc, Severine Cunat, Olivier Dereure, Pierre Dujols, Muriel Giansily-Blaizot, Christian Jorgensen, Amadou Konate, Dominique Larrey, Alain Le Quellec, Thibault Mura, Isabelle Raingeard, Jeanne Ramos, Eric Renard, Florence Rousseau, Jean-Francois Schved, Marie Christine Picot
Journal: Blood (2009)
PWE-150 Anaesthetic Support and Theatre Access for Emergency Endoscopy in Major Upper Gastrointestinal Bleeding (UGIB); Where Can We Improve?
Authors: TM Monaghan, D Evans, P Sugathan, T Archer, MW James
Journal: Gut (2016)

<h3>Introduction</h3> The 2015 NCEPOD “Time to get control” report recommends that hospitals admitting patients with severe UGIB have access to critical care and anaesthetic support for urgent endoscopy. We examined our emergency pathway including theatre urgency codes, time to therapy and clinical outcomes. <h3>Methods</h3> We analysed all patients who had emergency endoscopy in theatre for suspected severe UGIB at Queen’s Medical Centre, Nottingham, UK, between 1<sup>st</sup> March 2014 and 28<sup>th</sup> February 2015. We examined patient demographics, ASA and UGIB risk scores, shock index (SI; heart rate/systolic BP), referral times to endoscopy and breach rates, anaesthetic and operator details, endoscopic findings and therapy (blood product use, interventional radiology and surgery), procedural documentation, re-bleed plans, discharge location, complications and inpatient mortality. <h3>Results</h3> 95 patients (60 male mean [±SD] age 59.2 [±19.1]; 35 female, 55.2 [±28.4]) with suspected severe UGIB were treated in emergency theatres over the 12 month period. 93/95 (98%) had significant UGIB; 82% ASA grade ≥3 and Glasgow Blatchford Scores (GBS) were recorded in 18% of cases; median (range) score 12 (1–19). 64% were classified as theatre urgency 1 (U1; within 60 mins) and 25% U3 (within 180 mins). 64% of those in U1 had a high shock index (SI &gt; 0.9). However, median time from referral to endoscopy was 215 (range 37–1370) minutes. 47% breached the theatre urgency code times; including 59% of those assigned to U1. A consultant gastroenterologist was present in theatre in 86/95 (91%) of cases and 96% of patients received a general anaesthetic with rapid-sequence induction. The UGIB was non-variceal in 55/95 (58%; endoscopic intervention in 63%), variceal in 32/95 (34%), no cause found 8/95 (8%). 70% received a blood transfusion within 24 hrs of admission, mean 2.7(±2.5) units packed cells. 9/95 (10%) had CT angiography and 6/95 (6%) underwent coil embolization. No patients underwent surgery. An endoscopy report was generated for all cases, but re-bleed plans were only documented in 51%. Following endoscopy, 63/95 (67%) required a high-dependency bed and inpatient mortality was 21%. <h3>Conclusion</h3> Patients undergoing emergency endoscopy in theatre for acute UGIB had high risk scores and inpatient mortality, but 47% breached theatre urgency timings. These delays may impact on patient outcomes and are likely multifactorial. Potential reasons include time for resuscitation, transfer from admitting areas and co-ordination of emergency endoscopy teams and equipment. These logistics need to be understood more and improved to achieve improvements in patient care. <h3>Disclosure of Interest</h3> None Declared
Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy
Authors: Christian P. Pallasch, Leskov Ilya, Yadira M Soto, Christian J. Braun, Nadine Kutsch, Adam Drake, Lukas P. Frenzel, Bettina Iliopoulou, Nico van Rooijen, Clemens Wendtner, Michael Hallek, Jianzhu Chen, Michael T Hemann
Journal: Blood (2012)
Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study
Authors: Jacques Delaunay, Christian Recher, Arnaud Pigneux, Francis Witz, Norbert Vey, Odile Blanchet, Pascale Lefebvre, Isabelle Luquet, Isabelle Guillerme, Christelle Volteau, Emmanuel Gyan, Bruno Lioure, Eric Jourdan, Didier Bouscary, Romain Guieze, Edouard Randriamalala, Mario E Ojeda Uribe, Francois Dreyfus, Catherine Lacombe, Marie-christine Béné, Jean-Yves Cahn, Jean-Luc Harousseau, Norbert Ifrah
Journal: Blood (2011)
ATIM-13. PHASE I STUDY OF CHIMERIC ANTIGEN RECEPTOR-ENGINEERED T CELLS TARGETING IL13Rα2 FOR THE TREATMENT OF GLIOBLASTOMA
Authors: Christine Brown, Darya Alizadeh, Renate Starr, Lihong Weng, Jamie Wagner, Araceli Naranjo, Suzette Blanchard, Julie Kilpatrick, Jennifer Simpson, Julie Ann Ressler, Michael Jensen, Jana Portnow, Massimo D’Apuzzo, Michael Barish, Stephen Forman, Behnam Badie
Journal: Neuro-Oncology (2016)

T cell immunotherapy is emerging as a powerful strategy to treat cancer, and may offer opportunities to improve outcomes for patients with glioblastoma (GBM). We have optimized a chimeric antigen receptor (CAR) T cell therapy targeting the GBM-associated antigen IL13Rα2 that utilizes CD62L-enriched central memory T cells (Tcm) engineered by lentiviral transduction to express a second-generation 4-1BB-containing CAR (IL13BBζ). We report here initial findings from our first-in-human clinical trial [NCT02208362]. The aims of this trial include, (1) evaluation of the safety and feasibility of targeting IL13Rα2; and (2) comparison of intracranial delivery through intratumoral (with and without tumor resection) and intraventricular routes. To date, we have treated 10 patients and completed the first low-dose cohort of three resection patients. Local intracranial delivery of weekly IL13BBζ Tcm infusions has been safe and well-tolerated. Persisting CAR T cells were detected in the tumor cyst fluid or cerebral spinal fluid for a minimum of 7 days for patients with samples available. Evidence for CAR T cell bioactivity has been observed in a subset of patients, including decreased IL13Rα2 tumor antigen expression post-treatment. One patient of particular interest with recurrent multifocal GBM that included metastatic sites in the spine, was first treated with six weekly infusions of IL13BBζ Tcm into the resection cavity of the largest tumor, followed by ten weekly intraventricular infusions. In the absence of any other therapeutic interventions, this patient experienced a dramatic antitumor response with all intracranial and spinal tumors regressing 79%-97% by maximum area. This response was sustained for more than 7-months post-initiation of CAR T cell treatment. These early clinical findings suggest that intracranial delivery of second-generation IL13Rα2-targeted CAR T cells is safe and well-tolerated, and that CAR T cells are capable of eliciting potent antitumor responses against recurrent glioblastoma.
Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
Authors: Taxiarchis V. Kourelis, Surendra Dasari, Jason D. Theis, Marina Ramirez-Alvarado, Paul J. Kurtin, Morie A. Gertz, Steven R. Zeldenrust, Roman M. Zenka, Ahmet Dogan, Angela Dispenzieri
Journal: Blood (2016)
The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Sonya Parpart-Li, Bjarne Bartlett, Maria Popoli, Vilmos Adleff, Laura Tucker, Rebecca Steinberg, Andrew Georgiadis, Jill Phallen, Julie Brahmer, Nilo Azad, Ilene Browner, Daniel Laheru, Victor E. Velculescu, Mark Sausen, Luis A. Diaz
Journal: Clinical Cancer Research (2016)

Purpose: Analysis of genomic alterations in cell-free DNA (cfDNA) is evolving as an approach to detect, monitor, and genotype malignancies. Methods to separate the liquid from the cellular fraction of whole blood for circulating tumor DNA (ctDNA) analyses have been largely unstudied, although these may be a critical consideration for assay performance.Experimental Design: To evaluate the influence of blood processing on cfDNA and ctDNA quality and yield, we compared the cfDNA levels in serum with those in plasma. Given the limitations of serum for ctDNA analyses, we evaluated the effects of two plasma processing approaches, K2EDTA and Cell-Free DNA BCT (BCT) tubes, on cfDNA and ctDNA recovery. A total of 45 samples from nine patients with cancer were collected in both tube types. Once collected, blood was processed into plasma immediately or kept at room temperature and processed into plasma at 1, 3, 5, or 7 days.Results: As early as 24 hours after collection, plasma isolated from blood collected in K2EDTA tubes contained an elevated level of cfDNA that increased over time compared with BCT tubes where no significant increase in cfDNA levels was observed. When samples from an additional six patients with cancer, collected in the same manner, were stored at 4°C in K2EDTA tubes over the course of 3 days, total cfDNA and ctDNA levels were comparable between samples collected in BCT tubes. At day 3, there was a trend toward a decrease in ctDNA levels in both tubes that was more pronounced when measuring the mutant allele fraction for cases stored at 4°C in K2EDTA tubes.Conclusions: In summary, methods of blood processing have a strong influence on cfDNA and ctDNA levels and should be a consideration when evaluating ctDNA in peripheral circulation. Clin Cancer Res; 23(10); 2471-7. ©2016 AACR.
Tumor Antigen Small Guide (sg) RNA as a Completely Unique Nucleic Acid Medicine for Leukemia and Other Tumors.
Authors: Norihiro Watanabe, Miwako Narita, Akie Yamahira, Nozomi Tochiki, Takeshi Nakamura, Anri Saitoh, Masami Kaji, Tomoyo Taniguchi, Tatsuo Furukawa, Yoshifusa Aizawa, Masayuki Nashimoto, Masuhiro Takahashi
Journal: Blood (2009)
AB0563 Takayasu's Arteritis: Experience from A Tertiary Care Centre in Western India: Table 1.
Authors: P.S. Sagdeo, R. Samant, C. Balakrishnan, G. Mangat, T. Parikh, Y. Gc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Takayasu9s arteritis (TA) is a rare, granulomatous panarteritis of aorta and its major branches, most commonly presenting before the age of 40 years. There is limited data regarding epidemiology of TA from India. <h3>Objectives</h3> To describe the clinical profile and outcome of patients with Takayasu arteritis from a tertiary care centre in western India. <h3>Methods</h3> We analysed medical records of TA patients satisfying the 1990 Criteria of American College of Rheumatology for the Classification of Takayasu Arteritis attending Rheumatology Department from 2009 to 2014.Demographic, clinical, laboratory, imaging features and intervention done were noted. <h3>Results</h3> Forty Eight patients were included. Mean ESR at first visit of patients was 51mm/hr and last visit was 28 mm/hr. Mean ITAS at first visit was 10.9 and last visit was 0.6.CT angiography was used in 41%, PET was done in 70% and repeat PET was done in 35%. <h3>Conclusions</h3> 1. 12 (25%) patients were diagnosed in pre pulseless stage of disease. 2. As per angiographic classification class V disease was most common seen in our cohort. 3. 27% patients were refractory to treatment requiring surgical intervention. <h3>References</h3> Jain, S., Kumari, S., Ganguly, N. K. &amp; Sharma, B. K. Current status of Takayasu arteritis in India. Int. J. Cardiol.1996; 54 (Suppl.):S111-S116 Arend, W P; Michel, B A; Bloch, D A; Hunder, G G; Calabrese, L H et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis and rheumatism 1990 vol. 33 (8) p. 1129–34 <h3>Disclosure of Interest</h3> None declared
Vaginal Estrogens and Aromatase Inhibitors
Authors: Katherine Reeder-Hayes, Hyman B. Muss
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PTU-045 Device Assisted Enteroscopy in the United Kingdom: Description of A Large Tertiary Case Series Under Conscious Sedation
Authors: V Pattni, D Tate, A Terlevich, S Hughes, P Marden
Journal: Gut (2016)

<h3>Introduction</h3> Device assisted enteroscopy (DAE) has developed rapidly over the past decade, particularly with the advent of double balloon enteroscopy (DBE). The present study reports a case series from a tertiary centre for enteroscopy in the Southwest of the UK serving approximately 1 million people. Data was collected across three modalities of enteroscopy - DBE, Spiral enteroscopy (SE) and push enteroscopy (PE) - under conscious sedation. <h3>Methods</h3> Observational study of 343 enteroscopy procedures in 271 patients referred for enteroscopy from 2008 to 2014. Data were collected on patient demographics, procedure indications, diagnosis, sedation requirements, extent, duration, complications, tolerance and types of therapy performed. Completion rate was defined as a DAE procedure that changed patient management via therapy, diagnosis or normal finding. All patients who had procedures during the study period were included in the analysis. Ethical review was obtained from North Bristol NHS Trust local ethics committee. Comparison of numerical data was performed using t-test or one-way ANOVA analysis for comparison of multiple means. Comparison of categorical data was performed using chi-squared testing or correlation testing. <h3>Results</h3> Obscure GI bleeding (OGIB) was the commonest indication for DAE (n = 205, 59.7%). The overall yield of DAE was low (48.5%), with greater likelihood of positive findings if the indication was OGIB (55% vs 37.6%, p &lt; 0.001) and in older patients (mean age normal exam 60.0 vs. abnormal exam 66.5 years, p &lt; 0.001). Higher mean doses of midazolam were used for DBE from above (DBEa) (5.4 mg) and SE (5.6 mg) with lower doses for DBE from below (DBEb) (4.4 mg) and PE (3.8 mg). No serious complications were reported over the study period. SE was associated with shorter procedure time and shorter depth of insertion when compared to DBEa. Tolerance of DAE under conscious sedation was good with the majority (313/343, 91.2%) of procedures tolerated with comfort score 0 or 1 (out of 3). PE was significantly better tolerated whilst DBEb and SE were significantly worse tolerated than DBEa (p &lt; 0.001). Therapy was performed in 154/343 (44.9%) of procedures. Indications of OGIB (p = 0.021) and prior abnormal capsule endoscopy (p = 0.026) predicted performing therapy at DAE. Completion rates were more likely with DBEb (92.2% vs 69.9%, p &lt; 0.001) and less likely with PE (63% vs 77.8%, p = 0.006). <h3>Conclusion</h3> Small bowel enteroscopy under conscious sedation is safe and generally well tolerated. The procedure is of low yield; however this is a complex and extensively investigated cohort of patients. Nonetheless, small bowel enteroscopy should be used primarily for therapy once a diagnosis has been made by other modalities such as wireless capsule endoscopy. <h3>Disclosure of Interest</h3> None Declared
Dermatofibrosarcoma Protuberans in 3 Patients with ADA-SCID
Authors: Chimene Kesserwan, Robert A. Sokolic, Kerstin Heselmeyer, Clarymar Ortiz-Melendez, Jeffrey Cohen, Jaya Jagadeesh, Elizabeth Garabedian, Kristin Baird, Alan S. Wayne, Edward W. Cowen, Stefania Pittaluga, Chyi-Chia Richard Lee, Richard Sherry, Julia Bridge, Laura Finlayson, Noreen Walsh, Andrew Issekutz, Fabio Candotti
Journal: Blood (2008)
Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,
Authors: Marielle Wondergem, Josee Zijlstra, Nikie Hoetjes, Martine ED Chamuleau, Sonja Zweegman, Peter C. Huijgens, Ronald Boellaard, Otto s Hoekstra
Journal: Blood (2011)